Evidence map›Paper›PMID 40241988›Full record

ArticleFrontiers in endocrinology2025

Case Report: The long-term effects of the empagliflozin therapy on glycemia and renal function in a patient with Rabson-Mendenhall syndrome caused by two heterozygous variants in INSR gene.

Joanna Chrzanowska, Julia Lachowska, Maja Weimann, Agnieszka Zubkiewicz-Kucharska, Konstancja Fornalczyk, Katarzyna Kilis-Pstrusińska, Robert Smigiel

Abstract readCase Reports
PubMed Full text at PMC Publisher
In one paragraph

Article in Frontiers in endocrinology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors.

Joanna ChrzanowskaDepartment of Pediatrics, Endocrinology, Diabetology and Metabolic Diseases, Wroclaw Medical University, Wrocław, Poland.
Julia LachowskaDepartment of Pediatrics, Endocrinology, Diabetology and Metabolic Diseases, Wroclaw Medical University, Wrocław, Poland.
Maja WeimannDepartment of Pediatrics, Endocrinology, Diabetology and Metabolic Diseases, Wroclaw Medical University, Wrocław, Poland.
Agnieszka Zubkiewicz-KucharskaDepartment of Pediatrics, Endocrinology, Diabetology and Metabolic Diseases, Wroclaw Medical University, Wrocław, Poland.
Konstancja FornalczykDepartment of Pediatric Nephrology, Wroclaw Medical University, Wrocław, Poland.
Katarzyna Kilis-PstrusińskaDepartment of Pediatric Nephrology, Wroclaw Medical University, Wrocław, Poland.
Robert SmigielDepartment of Pediatrics, Endocrinology, Diabetology and Metabolic Diseases, Wroclaw Medical University, Wrocław, Poland.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

We present a patient with Rabson-Mendenhall syndrome with unsatisfactory glycemic control of diabetes despite the use of metformin, pioglitazone, and sitagliptin. We investigated the long-term effects of treatment with an empagliflozin. After one year of empagliflozin therapy, an improvement in metabolic control of diabetes was detected. However, eleven months after implementation of empagliflozin, the patient was diagnosed with an early form of nephrocalcinosis. The empagliflozin dose was reduced, maintaining metabolic control and reducing hypercalciuria. We discuss the probable causes of nephrocalcinosis as well as the potential impact of SGLT-2 inhibitor therapy on the occurrence and progression of renal calcium deposition.

Indexed as

Antigens, CDBenzhydryl CompoundsBlood GlucoseDonohue SyndromeGlucosidesReceptor, InsulinSodium-Glucose Transporter 2 InhibitorsHeterozygoteHumansHypoglycemic AgentsKidneyNephrocalcinosisAntigens, CDBenzhydryl CompoundsBlood GlucoseempagliflozinGlucosidesHypoglycemic AgentsINSR protein, humanReceptor, InsulinSodium-Glucose Transporter 2 Inhibitorsdiabetes mellitusinsulin resistancenephrocalcinosisRabson-Mendenhall syndromesodium–glucose cotransporter 2 inhibitors

Identifiers

PMID40241988
PMCPMC11999824

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.